CD117 ADC/In vivo HSC editing therapy(Crispr Therapeutics Ag)

N/A

Report date: 2025/10/20 14:18:13

Base Information

Drug NameCD117 ADC/In vivo HSC editing therapy(Crispr Therapeutics Ag)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionStem cell growth factor receptor inhibitors
TargetsStem cell growth factor receptor
Therapy Area/IndicationsHemoglobinopathiesbeta-ThalassemiaAnemia, Sickle Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCrispr Therapeutics Ag
China Registration ClassN/A

Develop Information

Active CompaniesCrispr Therapeutics AgVertex Pharmaceuticals Incorporated
Inactive CompaniesN/A
Active IndicationsHemoglobinopathiesbeta-ThalassemiaAnemia, Sickle Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A